Correlation of ASXL1 mutations with clinical data, FAB subtypes, and cytogenetic changes in patients with AML
| Variant . | Total (n = 501), n . | Mutation (n =54; 10.8%), n (%) . | Wild type (n = 447; 89.2%), n (%) . | P . |
|---|---|---|---|---|
| Age, y | < .001 | |||
| 15-29 | 75 | 5 (6.7) | 70 (93.3) | |
| 30-39 | 76 | 2 (2.6) | 74 (97.4) | |
| 40-49 | 87 | 7 (8.0) | 80 (92.0) | |
| 50-59 | 74 | 6 (8.1) | 68 (91.9) | |
| 60-69 | 80 | 12 (15.0) | 68 (85.0) | |
| 70-79 | 76 | 16 (21.1) | 60 (78.9) | |
| ≥ 80 | 33 | 6 (18.2) | 27 (81.8) | |
| Sex | .016 | |||
| Male | 285 | 39 (13.7) | 246 (86.3) | |
| Female | 216 | 15 (6.9) | 201 (93.1) | |
| FAB | ||||
| M0 | 10 | 4 (40.0) | 6 (60) | .016 |
| M1 | 112 | 4 (3.6) | 108 (96.4) | .003 |
| M2 | 171 | 22 (12.9) | 149 (87.1) | .278 |
| M3 | 38 | 0 (0) | 38 (100) | .025 |
| M4 | 124 | 19 (15.3) | 105 (84.7) | .060 |
| M5 | 25 | 4 (16.0) | 21 (84.0) | .332 |
| M6 | 12 | 0 (0) | 12 (100) | .628 |
| Undetermined | 9 | 1 (11.1) | 8 (88.9) | .974 |
| Cytogenetic | ||||
| Abnormal | 256 | 33 (12.9) | 223 (87.1) | |
| t(8;21) | 41 | 8 (19.5) | 33 (80.5) | .067 |
| inv(16) | 19 | 0 (0.0) | 19 (100.0) | .247 |
| t(15;17) | 38 | 0 (0.0) | 38 (100.0) | .025 |
| Isolated +8 | 19 | 6 (31.6) | 13 (68.4) | .011 |
| Complex | 49 | 1 (2.0) | 48 (98.0) | .047 |
| Normal | 192 | 17 (8.9) | 175 (91.1) | .179 |
| Variant . | Total (n = 501), n . | Mutation (n =54; 10.8%), n (%) . | Wild type (n = 447; 89.2%), n (%) . | P . |
|---|---|---|---|---|
| Age, y | < .001 | |||
| 15-29 | 75 | 5 (6.7) | 70 (93.3) | |
| 30-39 | 76 | 2 (2.6) | 74 (97.4) | |
| 40-49 | 87 | 7 (8.0) | 80 (92.0) | |
| 50-59 | 74 | 6 (8.1) | 68 (91.9) | |
| 60-69 | 80 | 12 (15.0) | 68 (85.0) | |
| 70-79 | 76 | 16 (21.1) | 60 (78.9) | |
| ≥ 80 | 33 | 6 (18.2) | 27 (81.8) | |
| Sex | .016 | |||
| Male | 285 | 39 (13.7) | 246 (86.3) | |
| Female | 216 | 15 (6.9) | 201 (93.1) | |
| FAB | ||||
| M0 | 10 | 4 (40.0) | 6 (60) | .016 |
| M1 | 112 | 4 (3.6) | 108 (96.4) | .003 |
| M2 | 171 | 22 (12.9) | 149 (87.1) | .278 |
| M3 | 38 | 0 (0) | 38 (100) | .025 |
| M4 | 124 | 19 (15.3) | 105 (84.7) | .060 |
| M5 | 25 | 4 (16.0) | 21 (84.0) | .332 |
| M6 | 12 | 0 (0) | 12 (100) | .628 |
| Undetermined | 9 | 1 (11.1) | 8 (88.9) | .974 |
| Cytogenetic | ||||
| Abnormal | 256 | 33 (12.9) | 223 (87.1) | |
| t(8;21) | 41 | 8 (19.5) | 33 (80.5) | .067 |
| inv(16) | 19 | 0 (0.0) | 19 (100.0) | .247 |
| t(15;17) | 38 | 0 (0.0) | 38 (100.0) | .025 |
| Isolated +8 | 19 | 6 (31.6) | 13 (68.4) | .011 |
| Complex | 49 | 1 (2.0) | 48 (98.0) | .047 |
| Normal | 192 | 17 (8.9) | 175 (91.1) | .179 |
Clinical data of white blood cell counts, hemoglobin levels, platelet counts, and lactate dehydrogenase levels were not different between patients with and without ASXL1 mutation and are not shown in the table. Cytogenetic data were available in 448 patients, including 50 with ASXL1 mutation and 398 without this mutation.
FAB indicates French-American-British.